Lipoprotein changes in children after liver transplantation: Mild hypertriglyceridemia and a decrease in HDL/HDL ratio

Esther Granot – 30 December 2003 – Hyperlipidemia is frequently observed in patients who undergo renal, cardiac, bone marrow, or liver transplantation, and its contribution to the long‐term morbidity and survival of patients with organ transplants may be substantial. In the few studies that have focused on the pediatric age group, findings have been inconsistent. The lipoprotein profile of 10 children after liver transplantation was characterized and compared with those in normal population controls and 10 healthy siblings.

Mallory body formation by ethanol feeding in drug‐primed mice

Zhi‐Qi Zhang‐Gouillon, Qi‐X. Yuan, Bing Hu, Norman Marceau, Barbara A. French, Karl Gaal, Yasuki Nagao, Y.‐J. Yvonne Wan, Samuel W. French – 30 December 2003 – Drug‐primed mice, created by a 5‐month feeding of diethyl‐1,4‐dihydro‐2,4,6‐trimethyl‐3,5‐pyridinedicarboxylate (DDC), followed by a 1‐month withdrawal, were refed ethanol or isocaloric dextrose (control) diets intragastrically for 7 days. The formation of Mallory bodies (MBs) was monitored by immunofluorescence and immunoperoxidase microscopy using antibodies to cytokeratin and ubiquitin, and also by electron microscopy.

Stimulation of inducible nitric oxide synthase in rat liver by hyaluronan fragments

Don C. Rockey, John J. Chung, Charlotte M. McKee, Paul W. Noble – 30 December 2003 – Hepatic injury and chronic wounding are characterized by increased synthesis of extracellular matrix proteins including hyaluronan (HA). Recently, it has been recognized that low‐molecular‐weight fragments of HA, but not native HA (e.g., high‐molecular‐weight HA), induce inflammatory gene expression, and activate the transcriptional regulator, nuclear factor κB (NF‐κB).

Dysregulation of proteoglycan production by intrahepatic biliary epithelial cells bearing defective (Delta‐f508) cystic fibrosis transmembrane conductance regulator

K. Ramakrishnan Bhaskar, Bradley S. Turner, Shelley A. Grubman, Douglas M. Jefferson, J.Thomas LaMont – 30 December 2003 – Hepatic dysfunction in cystic fibrosis (CF) has been attributed to accumulation of viscous mucoid secretions in intrahepatic bile ducts. The purpose of our study was to compare glycoconjugate secretion by intrahepatic biliary epithelial (IBE) cells derived from normal livers and livers of CF patients with the delta F508 mutation of the cystic fibrosis transmembrane conductance regulator (CFTR).

Therapy of hepatitis C: Cost‐effectiveness analysis

R S Koff – 30 December 2003 – The natural history of untreated chronic hepatitis C is controversial, and direct knowledge of the long‐term clinical and economic outcomes of current α interferon treatment regimens remains limited. Decision analytic models using available information on outcome probabilities and associated health care costs in the United States have been developed but are available only in abstract form.

Diagnostic tests for hepatitis C

D R Gretch – 30 December 2003 – Diagnostic tests for hepatitis C can be divided into the following two general categories: 1) serological assays that detect antibody to hepatitis C virus (anti‐HCV); and 2) molecular assays that detect, quantify, and/or characterize HCV RNA genomes within an infected patient. Serological assays have been subdivided into screening tests for anti‐HCV, such as the enzyme immunoassay (EIA), and supplemental tests such as the recombinant immunoblot assay (RIBA).

Humoral immune response to the E2 protein of hepatitis G virus is associated with long‐term recovery from infection and reveals a high frequency of hepatitis G virus exposure among healthy blood donors

M Tacke, S Schmolke, V Schlueter, S Sauleda, J I Esteban, E Tanaka, K Kiyosawa, H J Alter, U Schmitt, G Hess, B Ofenloch‐Haehnle, A M Engel – 30 December 2003 – The second envelope protein (E2) of the hepatitis G virus (HGV) was expressed in Chinese hamster ovary (CHO) cells and showed a molecular weight of approximately 60 to 70 kd, with 15 to 25 kd of the size contributed by N‐linked glycosylation. An enzyme‐linked immunosorbent assay (ELISA) using HGV‐E2 was developed to test for antibodies to this protein (anti‐E2) in human sera.

A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

P Lampertico, E Del Ninno, A Manzin, M F Donato, M G Rumi, G Lunghi, A Morabito, M Clementi, M Colombo – 30 December 2003 – Short‐term interferon treatment of serum hepatitis B e antigen (HBeAg)‐negative carriers with serum hepatitis B virus (HBV) DNA and histological features of chronic hepatitis B has been largely unsuccessful. In a pilot study of long‐term treatment, 42 such patients were randomly assigned to 6 million units of interferon alfa 2b (IFN‐α2b) three times per week for 24 consecutive months (n = 21, 4 with cirrhosis) or to no therapy (n = 21, 3 with cirrhosis).

Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus‐1b: No association with efficacy of interferon therapy or serum HCV‐RNA levels

C Yamamoto, N Enomoto, M Kurosaki, S Yu, J Tazawa, N Izumi, F Marumo, C Sato – 30 December 2003 – The extreme 5′‐proximal sequences of the hepatitis C virus (HCV) genome including the 5′untranslated region (5′UTR) and the first 30 nucleotides of the core region are highly conserved, and serve as an internal ribosome entry site (IRES) that initiates the cap‐independent translation of HCV polyprotein. Mutations in the IRES sequence have been shown to cause changes in the efficiency of protein translation in vitro.

Subscribe to